NOVACYT
Vélizy-villacoublay
About NOVACYT
The Novacyt Group is a rapidly growing, international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company’s lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high quality assays and reagents worldwide. The Group directly serves oncology, microbiology, haematology and serology markets as do its global partners, which include major corporates.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $43.3M
- Funding stage: IPO
- Last round: Post-IPO Debt (Nov 2019)
- Ticker: epa:ALNOV
- Website: novacyt.com
- Phone: +330139465104
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Life Science, Professional Services
Social Profiles
Canonical: https://fsome.com/organization/novacyt-126782 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.